Last $22.00 USD
Change Today +0.41 / 1.90%
Volume 365.9K
AEGR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

aegerion pharmaceuticals inc (AEGR) Snapshot

Open
$21.76
Previous Close
$21.59
Day High
$22.26
Day Low
$21.62
52 Week High
01/9/14 - $74.58
52 Week Low
10/31/14 - $19.10
Market Cap
625.6M
Average Volume 10 Days
667.7K
EPS TTM
$-1.55
Shares Outstanding
28.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AEGERION PHARMACEUTICALS INC (AEGR)

aegerion pharmaceuticals inc (AEGR) Related Businessweek News

No Related Businessweek News Found

aegerion pharmaceuticals inc (AEGR) Details

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. The company’s products include JUXTAPID (lomitapide) and LOJUXTA (lomitapide) hard capsules, an adjunct to a low-fat diet and other lipid-lowering treatments in patients with homozygous familial hypercholesterolemia. It also has the right to use lomitapide in the field of monotherapy or in combination with other dyslipidemic therapies for treatment of patients with other severe forms of hypercholesterolemia. The company distributes its products directly to patients and other purchasers through a specialty pharmacy. Aegerion Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Cambridge, Massachusetts.

268 Employees
Last Reported Date: 11/10/14
Founded in 2005

aegerion pharmaceuticals inc (AEGR) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $584.2K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $350.0K
Chief Operating Officer
Total Annual Compensation: $340.0K
Chief Medical Officer
Total Annual Compensation: $380.0K
Chief Regulatory Officer and Senior Vice Pres...
Total Annual Compensation: $320.0K
Compensation as of Fiscal Year 2013.

aegerion pharmaceuticals inc (AEGR) Key Developments

Aegerion Pharmaceuticals, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-13-2014 03:45 PM

Aegerion Pharmaceuticals, Inc. Presents at Boston Biotech NY/NJ CEO Conference, Nov-13-2014 03:45 PM. Venue: Apella, 450 East 29th Street, New York, New York, United States. Speakers: Craig E. Fraser, Chief Operating Officer.

Aegerion Pharmaceuticals, Inc., AstraZeneca PLC - Special Call

To discuss the Myalept acquisition

Aegerion Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Revenue Guidance for the Year 2014; Provides Revenue Guidance for the Year 2015

Aegerion Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net product sales of $43,674,000 compared to $16,330,000 a year ago. Loss from operations was $1,987,000 compared to $12,156,000 a year ago. Net loss before provision for income taxes was $5,673,000 compared to $12,303,000 a year ago. Net loss was $5,871,000 or $0.20 per basic and diluted share compared to $12,467,000 or $0.43 per basic and diluted share a year ago. Non-GAAP net income was $3,491,000 or $0.12 per basic share compared to non-GAAP net loss of $5,038,000 or $0.17 per basic share a year ago. The company achieved positive cash flow from operations of $8.7 million during the quarter. For the nine months period, the company reported net product sales of $106,661,000 compared to $24,051,000 a year ago. Loss from operations was $26,777,000 compared to $48,809,000 a year ago. Net loss before provision for income taxes was $30,742,000 compared to $49,342,000 a year ago. Net loss was $31,269,000 or $1.07 per basic and diluted share compared to $49,506,000 or $1.72 per basic and diluted share a year ago. Non-GAAP net loss was $5,382,000 or $0.18 per basic share compared to $31,673,000 or $1.10 per basic share a year ago. The company now expects full-year JUXTAPID net product sales to be between $150 million to $160 million, revised from the previous expectation of the lower end of the range of between $180 and $200 million. The company expects 2015 revenue growth of between 30% and 40% over 2014 projected revenue, taking into account forecasted prescription rates, drop-out rates, conversion trends, and the potential slowing impact on new patients starts following the anticipated launch of the PCSK-9 class of drugs in mid-2015, an impact Aegerion believes will ultimately be offset, in whole or part, through the identification of more HoFH patients as a result of the greater disease awareness likely to follow introduction of PCSK-9 inhibitors.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AEGR:US $22.00 USD +0.41

AEGR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AEGR.
View Industry Companies
 

Industry Analysis

AEGR

Industry Average

Valuation AEGR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.8x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AEGERION PHARMACEUTICALS INC, please visit www.aegerion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.